ABBV Jan 2023 165.000 call
| Previous close | 6.50 |
| Open | 5.69 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 165.00 |
| Expiry date | 2023-01-20 |
| Day's range | 5.69 - 6.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Zacks
AbbVie (ABBV) Gains But Lags Market: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $153.93, moving +0.08% from the previous trading session.
- Motley Fool
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.
- Motley Fool
3 Stocks You Can Buy and Hold for Decades
Three little words can make you a lot of money over the long term: Buy and hold. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying gravity.
